.png){kind=icon}
Interstitial Pulmonary Fibrosis (IPF) Bleomycin-Induced Lung Fibrosis
In rodents, a single intratracheal administration of Bleomycin leads to a well characterised response of 7-10 days of neutrophilic inflammation followed by a fibrotic response from around day 10 following bleomycin administration.
Currently there are only 2 approved drugs, that have been shown to slow the progression of Interstitial Pulmonary Fibrosis (IPF), nintedanib and pirfenidone.
Significant decreases in PV loops following bleomycin administration (Day 0) at Day 21, partially attenuated by therapeutic Pirfenidone Treatment
| Study Design | |
|---|---|
| Species/Strain | SD rat, C57BL/6J mouse |
| Model | Bleomycin induced fibrosis (single intratracheal administration) |
| Relevant Use | Assessing the efficacy of new compounds to slow the progression of IPF |
| Readouts Available | Daily Bodyweights and Clinical Signs, Lung Function (Resistance, Compliance, PV Loops), BAL differential cell counts, Bal TGF-β, BAL cytokines, Lung Hydroxyproline, Ashcroft Scoring and Pathology |
Study data generated by Labcorp Huntingdon Pharmacology.
Related Models
-
Bhas 42 Cell Transformation Assay (CTA)
Carcinogenicity, Discovery, Toxicology -
Asthma: Ovalbumin sensitization and challenge
Discovery -
Chlorine Induced Lung Injury
Discovery -
COPD: LPS + fMLP PK/PD model – Neutrophil Elastase Targets
Discovery -
COPD: Human Neutrophil Elastase Lung Hemorrhage Model
Discovery -
Bronchoconstriction models for LABA, LAMA & MABAs
Discovery -
Flu Model: H1N1 influenza lung infection model – viral COPD exacerbation
Discovery -
Model of Allergic Bronchopulmonary Aspergillosis (ABPA) in Mice
Discovery
